QQ客服 官方微博 反馈留言

	The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
	Xiong, Zuquan; Zang, Yiwen; Zhong, Shan; Zou, Lujia; Wu, Yishuo; Liu, Shenghua; Fang, Zujun; Shen, Zhoujun; Ding, Qiang; Chen, Shanwen
刊名	ONCOTARGET
	2017
卷号	8期号:18
关键词	renal cell carcinoma (RCC) mammalian target of rapamycin (mTOR) apoptosis XL388 MEK-ERK
ISSN号	1949-2553
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3617524
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xiong, Zuquan,Zang, Yiwen,Zhong, Shan,et al. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent[J]. ONCOTARGET,2017,8(18).
APA	Xiong, Zuquan.,Zang, Yiwen.,Zhong, Shan.,Zou, Lujia.,Wu, Yishuo.,...&Chen, Shanwen.(2017).The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.ONCOTARGET,8(18).
MLA	Xiong, Zuquan,et al."The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent".ONCOTARGET 8.18(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。